129 related articles for article (PubMed ID: 27708090)
1. Immune receptor for pathogenic α-synuclein.
Jucker M; Heikenwalder M
Science; 2016 Sep; 353(6307):1498-1499. PubMed ID: 27708090
[No Abstract] [Full Text] [Related]
2. Innate immunity regulates α-synuclein clearance.
Sawamura M; Uemura N; Takahashi R
Mov Disord; 2016 May; 31(5):638. PubMed ID: 26946483
[No Abstract] [Full Text] [Related]
3. Immunologic treatment of Parkinson's disease.
Jankovic J
Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
[No Abstract] [Full Text] [Related]
4. Sticking it to Parkinson's disease.
Leslie M
Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf46. PubMed ID: 15975896
[No Abstract] [Full Text] [Related]
5. Another Brick in the Wall.
Herwald H; Egesten A
J Innate Immun; 2019; 11(2):109-110. PubMed ID: 30808848
[No Abstract] [Full Text] [Related]
6. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Kim S; Seo JH; Suh YH
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
9. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
[TBL] [Abstract][Full Text] [Related]
11. A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity.
Stolzenberg E; Berry D; Yang D; Lee EY; Kroemer A; Kaufman S; Wong GCL; Oppenheim JJ; Sen S; Fishbein T; Bax A; Harris B; Barbut D; Zasloff MA
J Innate Immun; 2017; 9(5):456-463. PubMed ID: 28651250
[TBL] [Abstract][Full Text] [Related]
12. First therapy targeting Parkinson's proteins enters clinical trials.
Dolgin E
Nat Med; 2012 Jul; 18(7):992-3. PubMed ID: 22772533
[No Abstract] [Full Text] [Related]
13. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?
Romero-Ramos M; von Euler Chelpin M; Sanchez-Guajardo V
Hum Vaccin Immunother; 2014; 10(4):852-67. PubMed ID: 24670306
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
Olson KE; Gendelman HE
Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
[TBL] [Abstract][Full Text] [Related]
15. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.
Giasson BI; Jakes R; Goedert M; Duda JE; Leight S; Trojanowski JQ; Lee VM
J Neurosci Res; 2000 Feb; 59(4):528-33. PubMed ID: 10679792
[TBL] [Abstract][Full Text] [Related]
16. Development of Passive Immunotherapies for Synucleinopathies.
Bergström AL; Kallunki P; Fog K
Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
[TBL] [Abstract][Full Text] [Related]
17. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.
Gruden MA; Sewell RD; Yanamandra K; Davidova TV; Kucheryanu VG; Bocharov EV; Bocharova OA; Polyschuk VV; Sherstnev VV; Morozova-Roche LA
J Neuroimmunol; 2011 Apr; 233(1-2):221-7. PubMed ID: 21239064
[TBL] [Abstract][Full Text] [Related]
18. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
Gelders G; Baekelandt V; Van der Perren A
J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
[TBL] [Abstract][Full Text] [Related]
19. Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.
Labrie V; Brundin P
J Innate Immun; 2017; 9(5):437-440. PubMed ID: 28866688
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
